Conference
A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC).
Authors
Spreafico A; Chi KN; Sridhar SS; Smith DC; Carducci MA; Kavsak P; Wong TS; Wang L; Ivy SP; Mukherjee SD
Volume
31
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2013
Name of conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
May 31, 2013
Conference end date
June 4, 2013
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X